Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia


Por: Rossi, D, Rasi, S, Spina, V, Bruscaggin, A, Monti, S, Ciardullo, C, Deambrogi, C, Khiabanian, H, Serra, R, Bertoni, F, Forconi, F, Laurenti, L, Marasca, R, Dal-Bo, M, Rossi, FM, Bulian, P, Nomdedeu, J, Del Poeta, G, Gattei, V, Pasqualucci, L, Rabadan, R, Foa, R, Dalla-Favera, R, Gaidano, G

Publicada: 21 feb 2013
Resumen:
The identification of new genetic lesions in chronic lymphocytic leukemia (CLL) prompts a comprehensive and dynamic prognostic algorithm including gene mutations and chromosomal abnormalities and their changes during clonal evolution. By integrating mutational and cytogenetic analysis in 1274 CLL samples and using both a training-validation and a time-dependent design, 4 CLL subgroups were hierarchically classified: (1) high-risk, harboring TP53 and/or BIRC3 abnormalities (10-year survival: 29%); (2) intermediate-risk, harboring NOTCH1 and/or SF3B1 mutations and/or del11q22-q23 (10-year survival: 37%); (3) low-risk, harboring +12 or a normal genetics (10-year survival: 57%); and (4) very low-risk, harboring del13q14 only, whose 10-year survival (69.3%) did not significantly differ from a matched general population. This integrated mutational and cytogenetic model independently predicted survival, improved CLL prognostication accuracy compared with FISH karyotype (P < .0001), and was externally validated in an independent CLL cohort. Clonal evolution from lower to higher risk implicated the emergence of NOTCH1, SF3B1, and BIRC3 abnormalities in addition to TP53 and 11q22-q23 lesions. By taking into account clonal evolution through time-dependent analysis, the genetic model maintained its prognostic relevance at any time from diagnosis. These findings may have relevant implications for the design of clinical trials aimed at assessing the use of mutational profiling to inform therapeutic decisions.

Filiaciones:
Rossi, D:
 Amedeo Avogadro Univ Eastern Piedmont, Dept Translat Med, Div Hematol, I-28100 Novara, Italy

Rasi, S:
 Amedeo Avogadro Univ Eastern Piedmont, Dept Translat Med, Div Hematol, I-28100 Novara, Italy

Spina, V:
 Amedeo Avogadro Univ Eastern Piedmont, Dept Translat Med, Div Hematol, I-28100 Novara, Italy

Bruscaggin, A:
 Amedeo Avogadro Univ Eastern Piedmont, Dept Translat Med, Div Hematol, I-28100 Novara, Italy

Monti, S:
 Amedeo Avogadro Univ Eastern Piedmont, Dept Translat Med, Div Hematol, I-28100 Novara, Italy

Ciardullo, C:
 Amedeo Avogadro Univ Eastern Piedmont, Dept Translat Med, Div Hematol, I-28100 Novara, Italy

Deambrogi, C:
 Amedeo Avogadro Univ Eastern Piedmont, Dept Translat Med, Div Hematol, I-28100 Novara, Italy

Khiabanian, H:
 Columbia Univ, Dept Biomed Informat, New York, NY USA

 Columbia Univ, Ctr Computat Biol & Bioinformat, New York, NY USA

Serra, R:
 Amedeo Avogadro Univ Eastern Piedmont, Dept Translat Med, Lab Med Informat, I-28100 Novara, Italy

Bertoni, F:
 IOR Inst Oncol Res, Lymphoma & Genom Res Program, Bellinzona, Switzerland

 Oncol Inst Southern Switzerland, Lymphoma Unit, Bellinzona, Switzerland

Forconi, F:
 Univ Southampton, CRUK Clin Ctr, Canc Sci Unit, Southampton, Hants, England

 Univ Siena, Div Hematol, I-53100 Siena, Italy

Laurenti, L:
 Univ Cattolica Sacro Cuore, Inst Hematol, I-00168 Rome, Italy

Marasca, R:
 Univ Modena & Reggio Emilia, Dept Hematol & Oncol, Div Hematol, Modena, Italy

Dal-Bo, M:
 Ctr Riferimento Oncol, I-33081 Aviano, Italy

Rossi, FM:
 Ctr Riferimento Oncol, I-33081 Aviano, Italy

Bulian, P:
 Ctr Riferimento Oncol, I-33081 Aviano, Italy

Nomdedeu, J:
 Hosp Santa Creu & Sant Pau, Dept Hematol & Lab, Barcelona, Spain

Del Poeta, G:
 Univ Roma Tor Vergata, Dept Hematol, Rome, Italy

Gattei, V:
 Ctr Riferimento Oncol, I-33081 Aviano, Italy

Pasqualucci, L:
 Columbia Univ, Inst Canc Genet, New York, NY USA

 Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA

 Columbia Univ, Dept Pathol & Cell Biol, New York, NY USA

 Univ Perugia, Dept Hematol & Clin Immunol, Inst Hematol, I-06100 Perugia, Italy

Rabadan, R:
 Columbia Univ, Dept Biomed Informat, New York, NY USA

 Columbia Univ, Ctr Computat Biol & Bioinformat, New York, NY USA

Foa, R:
 Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, Div Hematol, I-00185 Rome, Italy

Dalla-Favera, R:
 Columbia Univ, Inst Canc Genet, New York, NY USA

 Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA

 Columbia Univ, Dept Pathol & Cell Biol, New York, NY USA

 Columbia Univ, Dept Genet & Dev, New York, NY USA

Gaidano, G:
 Amedeo Avogadro Univ Eastern Piedmont, Dept Translat Med, Div Hematol, I-28100 Novara, Italy
ISSN: 00064971





BLOOD
Editorial
AMER SOC HEMATOLOGY, 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA, USA
Tipo de documento: Article
Volumen: 121 Número: 8
Páginas: 1403-1412
WOS Id: 000321750000025
ID de PubMed: 23243274
imagen Green Published, Bronze

MÉTRICAS